Ustekinumab for extra-intestinal manifestations of inflammatory bowel disease: a systematic literature review.

Date publication

décembre 2020

Journal

Journal of Crohn's & colitis

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
Guillo L, D'Amico F, Danese S, Peyrin-Biroulet L

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/33367674

Résumé

Extraintestinal manifestations (EIMs) are frequent in patients with inflammatory bowel diseases (IBD) and a challenging condition to manage. Tumor necrosis factor alpha antagonists (anti-TNFα) are recognized as the primary therapeutic option. We aimed to summarize evidence on the efficacy of ustekinumab for the treatment of EIMs.

Mots clés

Crohn disease, Inflammatory bowel diseases, extra-intestinal manifestations, ulcerative colitis, ustekinumab

Référence

J Crohns Colitis. 2020 Dec 24;: